Raltitrexed

Generic Name: Raltitrexed

Brand Names: Tomudex

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₂N_₄O_₆S

CAS Number: 112887-68-0

Unique Ingredient Identifier: FCB9EGG971

Background: Raltitrexed (brand name Tomudex®) is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase.

Indication: For the treatment of malignant neoplasm of colon and rectum

Associated Conditions: Advanced Colorectal Cancer, Pleural Mesotheliomas

Associated Therapies: -

Clinical Trials

Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus

Phase 2

Conditions: Esophagus Squamous Cell Carcinoma

Interventions: Drug: raltitrexed

First Posted Date: 2018-07-13

Last Posted Date: 2021-04-06

Lead Sponsor: Huai'an First People's Hospital

Target Recruit Count: 32

Registration Number: NCT03585530

Locations: 🇨🇳
Huai'an First Hospital, Huai'an, Jiangsu, China

Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection

Phase 2

Conditions: Gastric Cancer

Interventions: Drug: Raltitrexed
Radiation: postoperative radiotherapy

First Posted Date: 2018-01-05

Last Posted Date: 2018-01-05

Lead Sponsor: Zhongnan Hospital

Target Recruit Count: 48

Registration Number: NCT03392103

Locations: 🇨🇳
Zhongnan Hopital of Wuhan University, Wuhan, Hubei, China

Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC.

Phase 4

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Raltitrexed
Radiation: Intensity Modulated Radiotherapy

First Posted Date: 2017-06-23

Last Posted Date: 2020-08-07

Lead Sponsor: The First Affiliated Hospital of Dalian Medical University

Target Recruit Count: 202

Registration Number: NCT03196843

Locations: 🇨🇳
Lv Xiupeng, Dalian, Liaoning, China

Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

Phase 2

Conditions: Advanced Colorectal Cancer

Interventions: Drug: Raltitrexed
Drug: Irinotecan
Drug: Oxaliplatin
Drug: Bevacizumab

First Posted Date: 2017-04-24

Last Posted Date: 2021-08-30

Lead Sponsor: Jiangsu Cancer Institute & Hospital

Target Recruit Count: 100

Registration Number: NCT03126071

Locations: 🇨🇳
Nantong Tumor Hospital, Nantong, Jiangsu, China
🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳
Jiangsu Cancer Institute & Hospital, Nanjing, Jiangsu, China

and more 1 locations

Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 2

Completed

Conditions: Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Raltitrexed
Drug: Paclitaxel

First Posted Date: 2017-03-20

Last Posted Date: 2021-02-01

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 41

Registration Number: NCT03083613

Locations: 🇨🇳
Chinese Academy of Medical Sciences, Beijing, China

Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients

Phase 2

Conditions: ColoRectal Cancer

Interventions: Drug: Irinotecan
Drug: Raltitrexed

First Posted Date: 2017-02-14

Last Posted Date: 2017-02-14

Lead Sponsor: China Medical University, China

Target Recruit Count: 100

Registration Number: NCT03053167

Locations: 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China

Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly

Phase 2

Completed

Conditions: Rectal Neoplasms Malignant

Interventions: Radiation: Preoperative radiation
Drug: Raltitrexed
Procedure: Pelvic surgery

First Posted Date: 2016-12-14

Last Posted Date: 2021-09-09

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 68

Registration Number: NCT02992886

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China

Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer

Phase 3

Conditions: Head and Neck Squamous Cell Cancer

Interventions: Drug: Raltitrexed
Drug: 5-fluorouracil
Drug: Cisplatin
Radiation: IMRT

First Posted Date: 2015-06-30

Last Posted Date: 2015-06-30

Lead Sponsor: Jiangsu Cancer Institute & Hospital

Target Recruit Count: 120

Registration Number: NCT02485548

Locations: 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China

Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients

Phase 2

Conditions: Colorectal Carcinoma

Interventions: Drug: Raltitrexed
Drug: Irinotecan
Drug: 5-fluorouracil
Drug: Leucovorin

First Posted Date: 2015-03-03

Last Posted Date: 2015-03-03

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT02376452

Locations: 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China

Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases

Phase 4

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Raltitrexed
Drug: Oxaliplatin
Drug: lipiodol

First Posted Date: 2013-10-09

Last Posted Date: 2017-03-13

Lead Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical

Target Recruit Count: 320

Registration Number: NCT01959061

Locations: 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy